Clinical Trial Update: Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of cetuximab, irinotecan, and toripalimab in right-sided, RAS/BRAF wild-type metastatic colorectal cancer; recruitment …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Camptosar (irinotecan)
• ERBITUX (cetuximab)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Colorectal Cancer Metastatic | Phase 2 | Status: RECRUITING